Last week's #OncFive:

✅ Pirtobrutinib OK'd in 1L CLL/SLL #lymsm #leusm
🎗️ Priority review: elinzanetant for breast cancer #bcsm
🩸 Tabelecleucel BLA resubmitted in EBV+ PTLD
🫁 Savolitinib+osimertinib NDA in MET+ NSCLC #lcsm
🫁 Zipalertinib NDA starts in NSCLC

🔗: www.onclive.com/view/the-onc...

🌟 Last week's #OncFive 🌟:
🎗️ @fda.gov approved camizestrant+CDK4/6 inihibition for ESR1-mutated breast cancer
🩸 Ropeginterferon alfa-2b approved for ET
🫁 Daraxonrasib produced durable ORR in RAS-mutated NSCLC
➕ Many more!

Learn more 🔗: www.onclive.com/view/the-onc...